News & Updates

Preventing respiratory syncytial virus (RSV) in infants can be achieved through maternal vaccination with the RSV prefusion F protein (RSVpreF) vaccine or administration of the monoclonal antibody nirsevimab—strategies endorsed by the WHO. In a French population-based cohort study, nirsevimab has been associated with lower risks of RSV-related hospitalizations and severe outcomes.

A recent study has shown the comparable effectiveness of fixed (fCPAP) and auto-titrating continuous positive airway pressure (APAP), with some outcomes favouring fCPAP, in patients with obesity hypoventilation syndrome (OHS) and severe obstructive sleep apnoea (sOSA).

Certain food groups may influence the risk of asthma in Asians, with a study suggesting a protective benefit with fruit and nuts and a potential risk increase with seafood.

Anxiety appears to influence asthma severity in adolescents, as shown in a recent cross-sectional study.

Treatment with nirsevimab helps reduce hospitalizations and emergency department (ED) visits associated with lower respiratory tract infections (LRTIs) in infants and young children, according to the results of a meta-analysis.

New drug applications approved by US FDA as of 1-15 February 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.